2. Stem Cell/Wnt Cytoskeleton
  3. β-catenin Wnt Collagen
  4. PTD-DBM

PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

PTD-DBM

PTD-DBM 構造式

CAS 番号 : 1609454-11-6

容量 価格（税別） 在庫状況 数量
1 mg $70 在庫あり
5 mg $185 在庫あり
10 mg $300 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

PTD-DBM 関連抗体

Top Publications Citing Use of Products

Wnt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing[1][2][3].

体外実験

PTD-DBM (10 μM; 72 h) restores Wnt/β-catenin signaling and proliferation marker expression in PGD2-treated HaCaT cells[1].
PTD-DBM (2-10 μM; 24 h-2 d) activates Wnt/β-catenin signaling and promotes myofibroblast differentiation, collagen production, collagen gel contraction, and cell migration in human dermal fibroblasts in vitro in a concentration-dependent manner, with effects abolished by β-catenin knockdown or bosentan, and synergistically enhanced by co-treatment with Wnt3a[3].
PTD-DBM (2 μM; 2 d) synergistically enhances Wnt/β-catenin activation with Wnt3a in HaCaT keratinocytes, increasing β-catenin expression[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PTD-DBM 関連抗体
体内実験

PTD-DBM (10 mM; topical; every other day; 8 to 12 or 20 days post-depilation) restores PGD2-induced alopecia in C57BL/6N mice by reactivating Wnt/β-catenin signaling and hair follicle proliferation, recovering hair shaft length to control levels[1].
PTD-DBM (10 mM; topical; daily; 7 to 21 or 25 days post-wounding) restores PGD2-impaired wound-induced hair follicle neogenesis in C57BL/6N mice by reactivating Wnt/β-catenin signaling and regenerative markers, recovering neogenic follicle counts to control levels[1].
PTD-DBM (100 μM; topical; daily; 11 days) alone accelerates cutaneous wound healing and increases collagen production in mice, while PTD-DBM (100 μM + 500 mM VPA; topical; daily; 11 days) co-treatment with VPA synergistically enhances these effects, with no induction of oncogenic markers c-Myc or cyclin D1[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6N wild-type (7-week-old male; dorsal skin depilation-induced hair cycle synchronization, topical PGD2 exposure-induced hair growth suppression)[1]
Dosage: 10 mM
Administration: topical; every other day; 8 to 12 or 20 days post-depilation
Result: Restored PGD2-suppressed hair shaft length to levels comparable to untreated control mice.
Restored nuclear β-catenin fluorescence intensity and PCNA protein expression in skin tissues, which were reduced by PGD2 exposure.
Animal Model: C57BL/6N wild-type (3-week-old; full-thickness dorsal skin wound, topical PGD2 exposure-induced hair follicle regeneration suppression)[1]
Dosage: 10 mM
Administration: topical; daily; 7 to 21 or 25 days post-wounding
Result: Restored PGD2-suppressed neogenic hair follicle counts (measured via ALP staining) to levels comparable to untreated control mice.
Induced expression of WIHN markers (fgf9, keratin 17), as well as β-catenin and PCNA protein expression in wounded skin tissues, which were reduced by PGD2 exposure.
Animal Model: C3H mice (7-week-old male)[3]
Dosage: 100 μM (single-agent); 100 μM + 500 mM VPA (combination)
Administration: topical; daily; 11 days
Result: Accelerated cutaneous wound healing to a degree comparable to EGF treatment, reaching ~90% wound closure by day 12.
Increased β-catenin levels in wound tissue, and induced increases in keratin 14, collagen I, PCNA, and endothelin-1 expression in wound keratinocytes and fibroblasts.
Induced significantly greater increases in β-catenin, keratin 14, collagen I, PCNA, endothelin-1, and phosphorylated ERK in wound tissue compared to single-agent treatments or EGF.
分子量

3082.64

分子式

C124H225N61O28S2
CAS 番号
Appearance

Solid

Color

White to off-white

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys
Sequence Shortening

RRRRRRRRGGGGRKTGHQICKFRKC
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

H2O : ≥ 100 mg/mL (32.44 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.3244 mL 1.6220 mL 3.2440 mL
5 mM 0.0649 mL 0.3244 mL 0.6488 mL
10 mM 0.0324 mL 0.1622 mL 0.3244 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
純度とドキュメンテーション
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 0.3244 mL 1.6220 mL 3.2440 mL 8.1099 mL
5 mM 0.0649 mL 0.3244 mL 0.6488 mL 1.6220 mL
10 mM 0.0324 mL 0.1622 mL 0.3244 mL 0.8110 mL
15 mM 0.0216 mL 0.1081 mL 0.2163 mL 0.5407 mL
20 mM 0.0162 mL 0.0811 mL 0.1622 mL 0.4055 mL
25 mM 0.0130 mL 0.0649 mL 0.1298 mL 0.3244 mL
30 mM 0.0108 mL 0.0541 mL 0.1081 mL 0.2703 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PTD-DBM Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PTD-DBM1609454-11-6β-cateninWntCollagenBeta catenincutaneous woundHaCaT cellsandrogenetic alopeciaWnt/β-catenin pathwayDvlCXXC5CXXC5-Dvlhuman dermal fibroblastsC57BL/6N miceInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
PTD-DBM
製品番号:
HY-P11112
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.